Does Turmeric Help With Weight Loss? Honest Evidence Review

Turmeric (and its active compound curcumin) produces modest weight-loss effects (SMD -0.23 for body weight, SMD -0.37 for BMI across 21 RCTs per Akbari 2019 PMID 31249528) — a small effect mediated by anti-inflammatory pathways. The magnitude is roughly 1/15th to 1/25th of FDA-approved GLP-1s like Wegovy (~15% TBWL per STEP-1) and Zepbound (~21% TBWL per SURMOUNT-1). Raw dietary turmeric has minimal systemic effect because curcumin has poor oral bioavailability (Shoba 1998 PMID 9619120: serum levels “undetectable or very low” after 2 g curcumin alone); bioavailability-enhanced formulations (Meriva, Theracurmin, Longvida, BCM-95, curcumin + piperine) drive most positive trial outcomes.

Turmeric (Curcuma longa) is the ground rhizome of a flowering ginger-family plant native to South Asia. It has been used for thousands of years in Indian and Ayurvedic cooking and medicine and is the source of the deep yellow color in curry and in “golden milk” TikTok recipes. The two highest-volume 2026 Google queries in this cluster ask “does turmeric help with weight loss” and the related “how much weight can you lose with turmeric.” This article answers both from the verified primary-source literature.

The short, evidence-led answer: yes, but the magnitude is small, the mechanism is anti-inflammatory rather than fat-burning, the effect appears largest in patients with inflammation-driven obesity (NAFLD, metabolic syndrome, elevated CRP), and the gap between turmeric and FDA-approved anti-obesity medications is more than an order of magnitude. Turmeric is a reasonable adjunct for the right patient phenotype, not a primary weight-loss tool. For the broader supplement-vs-AOM evidence framework, see our supplements weight-loss evidence-grade hub.

1. Turmeric vs curcumin — the most important distinction

Almost every confused turmeric-and-weight-loss conversation starts with a category error. Turmeric is not curcumin. Turmeric is the whole dried rhizome of Curcuma longa as sold in a spice jar. Curcumin is a specific polyphenol (one of three closely-related “curcuminoids” alongside demethoxycurcumin and bisdemethoxycurcumin) that makes up only about 2 to 5 percent of turmeric powder by weight.

That ratio matters enormously when you are reading a trial. A published RCT showing benefit at “1,000 mg/day of curcumin” is testing roughly the curcumin content of 20 to 50 g (about 7 to 17 teaspoons) of culinary turmeric powder per day. Nobody eats that much spice. Almost all of the clinical evidence for weight, inflammation, NAFLD, and joint pain uses standardized curcumin extracts, not raw turmeric in food.

The implication: cooking with turmeric is fine and pleasant and will deliver near-zero systemic curcumin. The published weight-loss evidence uses standardized extracts at 500 to 2,000 mg curcuminoid-equivalent per day, usually formulated to increase bioavailability. If you are reading a label that simply says “turmeric 500 mg” with no “standardized to X% curcuminoids” statement and no bioavailability enhancer, you are taking a barely-active supplement.

2. The Akbari 2019 meta-analysis — the headline number

The most-cited body-weight evidence base for curcumin is the Akbari, Lankarani, Tabrizi, Ghayour-Mobarhan, Peymani, Ferns, Ghaderi, and Asemi meta-analysis published in Frontiers in Pharmacology in 2019^[1]. The paper pooled 18 articles (21 separate studies) totaling 1,604 individuals randomized to curcumin or placebo for an analysis of weight, BMI, waist circumference, and adipokines in metabolic syndrome and related disorders.

The PubMed abstract states, verbatim:

“Eighteen articles (21 studies) that comprised a total of 1,604 individuals were finally included in the meta-analysis. Curcumin intake significantly reduced body mass index (BMI) (SMD -0.37; 95% CI, -0.61, -0.13; P < 0.01), weight (SMD -0.23; 95% CI, -0.39, -0.06; P < 0.01), waist-circumference (WC) (SMD -0.25; 95% CI, -0.44, -0.05; P = 0.01), leptin levels (SMD -0.97; 95% CI, -1.18, -0.75; P < 0.001) and increased adiponectin levels (SMD 1.05; 95% CI, 0.23, 1.87; P = 0.01). We found no significant effect of curcumin intake on hip ratio (HR) (SMD -0.17; 95% CI, -0.42, 0.08; P = 0.18).”^[1]

Three things to read carefully:

• The effects are reported as standardized mean differences (SMDs), not raw kilograms. A widely-shared claim on supplement-blog summaries that curcumin caused “-0.65 kg of weight loss” in this paper does not appear in the PubMed abstract. We omit unverifiable raw-kg translations and report only the SMDs as published.
• An SMD of -0.23 is a small effect size by conventional standards. Cohen's benchmarks classify SMDs of 0.2, 0.5, and 0.8 as small, medium, and large respectively. Curcumin's body-weight effect across 21 RCTs lands in the “small” bucket. The BMI effect (SMD -0.37) is larger and lands between small and medium. The leptin effect (SMD -0.97) is the largest signal in the paper and is what drives the mechanistic story below.
• The population was metabolic syndrome and related disorders, not general-population overweight adults. Inflammation-driven phenotypes (high CRP, insulin resistance, NAFLD, type 2 diabetes) were the dominant included populations. The result does not necessarily generalize to a metabolically healthy overweight adult who simply wants to drop 10 kg.

2.1 What “SMD -0.23 for body weight” means in plain English

A standardized mean difference of -0.23 means the curcumin group weighed, on average, about 0.23 standard-deviations less than the placebo group at trial end. Across the included RCTs, the between-group difference in raw kilograms typically falls in the 1 to 3 kg range over 8 to 24 weeks of treatment, but the exact kilogram differs by trial because trials had different baseline weights, durations, and curcumin formulations. The honest summary: single-digit kilograms over 2 to 6 months in metabolic-syndrome adults. We avoid asserting a more specific kg figure than the underlying primary source supports.

2.2 The Lukkunaprasit 2023 update — same direction, NAFLD population

The Lukkunaprasit et al. 2023 updated meta-analysis^[4] pooled 6 systematic reviews and 16 RCTs of curcumin in metabolic dysfunction-associated fatty liver disease (MAFLD/NAFLD). The PubMed abstract states, verbatim:

“curcumin demonstrated significant improvement in aspartate and alanine aminotransferase with pooled mean difference [95% confidence interval (CI)] of -3.90 (-5.97, -1.82) and -5.61 (-9.37, -1.85) units/L, respectively. Resolution and improvement of hepatic steatosis was higher in curcumin than control group with pooled relative risk (95% CI) of 3.53 (2.01, 6.22) and 3.41 (1.36, 8.56), respectively. Curcumin supplementation also led to lower fasting blood sugar, body mass index, and total cholesterol.”^[4]

Two clinically useful signals: (1) curcumin produces measurable liver-enzyme improvements (AST -3.9 U/L and ALT -5.6 U/L), and (2) hepatic steatosis is more likely to resolve or improve under curcumin than under placebo (RR 3.53 for resolution, RR 3.41 for improvement). The BMI improvement noted is consistent with Akbari 2019 — the same direction, the same modest magnitude, the same NAFLD/metabolic-syndrome population. For the broader question of whether GLP-1s themselves protect the liver, see our does GLP-1 cause liver damage? NAFLD/NASH evidence review.

3. The Panahi 2017 phytosomal-curcumin NAFLD RCT — the cleanest single trial

Among the individual RCTs in the meta-analyses above, the Panahi, Kianpour, Mohtashami, Jafari, Simental-Mendia, and Sahebkar 2017 trial published in Drug Research^[3] is one of the cleanest and most-cited. 102 patients with NAFLD (grades 1 to 3 on liver ultrasonography) were randomized to phytosomal curcumin 1,000 mg/day in two divided doses (Meriva-type phospholipid carrier) or placebo for 8 weeks; 87 completed. The abstract reports, verbatim:

“Supplementation with curcumin was associated with a reduction in body mass index (-0.99 +/- 1.25 vs -0.15 +/- 1.31 in the curcumin and placebo groups, respectively; p=0.003) and waist circumference (-1.74 +/- 2.58 vs -0.23 +/- 3.49 in the curcumin and placebo groups, respectively; p=0.024). Ultrasonographic findings were improved in 75.0% of subjects in the curcumin group, while the rate of improvement in the control group was 4.7% (p<0.001). Serum levels of aspartate aminotransferase and alanine aminotransferase were reduced by the end of trial in the curcumin group (p<0.001) but elevated in the control group (p<0.001). Curcumin was safe and well tolerated throughout the trial.”^[3]

Translating: in 8 weeks, the curcumin group dropped about 1 kg/m^2 of BMI and 1.7 cm of waist circumference relative to placebo, with ultrasonographically-detected liver steatosis improving in 75% of patients versus 4.7% on placebo. The BMI delta corresponds to roughly 2.5 to 3 kg for an average adult over 8 weeks — small in absolute terms but real.

4. Why bioavailability is everything — the Shoba 1998 paper

The single most important pharmacokinetic finding in the curcumin literature is from Shoba, Joy, Joseph, Majeed, Rajendran, and Srinivas, published in Planta Medica in 1998^[2]. The trial measured curcumin serum levels in rats and in healthy human volunteers after a 2 g oral dose of curcumin alone, then again after the same 2 g dose plus 20 mg of piperine (the active alkaloid in black pepper, also marketed as BioPerine). The abstract states, verbatim:

“The medicinal properties of curcumin obtained from Curcuma longa L. cannot be utilised because of poor bioavailability due to its rapid metabolism in the liver and intestinal wall. ... in humans after a dose of 2 g curcumin alone, serum levels were either undetectable or very low. Concomitant administration of piperine 20 mg produced much higher concentrations from 0.25 to 1 h post drug (P < 0.01 at 0.25 and 0.5 h; P < 0.001 at 1 h), the increase in bioavailability was 2000%. The study shows that in the dosages used, piperine enhances the serum concentration, extent of absorption and bioavailability of curcumin in both rats and humans with no adverse effects.”^[2]

Two important implications:

• Plain dietary turmeric has minimal systemic effect. Raw oral curcumin is poorly absorbed, rapidly conjugated in the gut wall and liver, and excreted before reaching most target tissues. A teaspoon of turmeric in food delivers a curcumin dose that is barely measurable in the bloodstream.
• Almost all positive RCTs used a bioavailability enhancer. Piperine, phytosome carriers (Meriva), colloidal nanoparticles (Theracurmin), solid-lipid particles (Longvida), turmeric-essential-oil co-formulation (BCM-95) — these were developed specifically to solve the bioavailability problem. When you read a positive curcumin trial, look for which formulation was used. Generic 500 mg curcumin extract without an enhancer is not the same intervention.

4.1 The bioavailability-enhanced formulation landscape

Editorial note on bioavailability claims: the “Xx more absorbed” numbers above are manufacturer-reported relative bioavailability under controlled pharmacokinetic conditions and should be read as “measurably more absorbed than raw curcumin” rather than as the literal multiplier of clinical benefit. The clinical-trial endpoints (weight, BMI, ALT, joint pain, mood) do not scale linearly with serum curcumin AUC.

5. The anti-inflammatory mechanism — NF-kB, PPAR-gamma, AMPK

Curcumin's biological effects are not primarily metabolic. It is an anti-inflammatory polyphenol with a well-characterized molecular fingerprint that includes:

• NF-kappa-B inhibition. Curcumin blocks IkappaB-kinase (IKK) activation, preventing the nuclear translocation of NF-kB and downstream transcription of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1-beta). Visceral adipose tissue is a chronic low-grade inflammatory compartment in obesity, and lowering NF-kB tone there is the dominant proposed mechanism for the modest weight, BMI, and waist-circumference effects in the meta-analyses.
• PPAR-gamma modulation. Curcumin acts as a partial PPAR-gamma agonist in adipocyte assays, with effects on adipocyte differentiation and lipid storage opposite in direction to high-dose thiazolidinediones — i.e., favoring smaller, more-insulin-sensitive adipocytes rather than large, lipid-laden, hypertrophic ones.
• AMP-K activation. Curcumin activates AMP-activated protein kinase (AMPK), the cellular energy-sensing pathway that promotes fatty-acid oxidation and inhibits lipogenesis. This is the same pathway through which metformin and berberine act (see our berberine vs GLP-1 evidence review for the comparable mechanism story).
• White-to-brown adipocyte phenotype. Lone, Choi, Kim, and Yun 2016^[5]showed that curcumin induces brown-fat-like gene expression (UCP1, PRDM16, PGC1-alpha) in 3T3-L1 and primary white adipocytes in vitro, with increased mitochondrial biogenesis and enhanced lipolysis via beta3-adrenergic and AMPK activation. The abstract states, verbatim: “curcumin induces browning of 3T3-L1 and primary white adipocytes via enhanced expression of brown fat-specific genes ... Curcumin enhanced lipolysis through the activation of beta3-adrenergic receptor (beta3-AR) and AMP-activated protein kinase (AMPK).”^[5] This is a cell-culture mechanism paper, NOT a clinical trial; we cite it as a plausible mechanism, not as evidence of human weight loss.

The picture that emerges across the molecular evidence: curcumin is a multi-target anti-inflammatory and metabolic-tone modulator. The size of the clinical signal is small because the mechanism is indirect (you have to lower inflammation, which has to translate to better adipose-tissue function, which has to translate to fat loss) and because curcumin's bioavailability remains modest even with carrier formulations.

5.1 Why effects appear largest in “inflammation-driven” obesity

Curcumin's mechanism predicts — and the meta-analytic evidence confirms — that the patients most likely to respond are those with high baseline inflammatory tone:

• Elevated high-sensitivity CRP (>3 mg/L), where curcumin reduces CRP across multiple trials.
• NAFLD or MAFLD, where the Panahi 2017 phytosomal-curcumin trial^[3] and the Lukkunaprasit 2023 meta-analysis^[4] both show ALT/AST normalization and steatosis improvement.
• Metabolic syndrome with high leptin, where the Akbari 2019 meta-analysis^[1] showed the largest effect size in the entire paper was on leptin (SMD -0.97).
• Insulin resistance / prediabetes, where the combined inflammation-plus-insulin-resistance phenotype responds to anti-inflammatory interventions.

A metabolically healthy overweight adult with normal CRP, normal ALT, normal fasting glucose, and normal leptin has very little substrate for curcumin to act on. The expected weight effect in that population is closer to zero than to the meta-analytic average.

6. Magnitude vs FDA-approved anti-obesity medications

For magnitude context, the order-of-magnitude gap between turmeric/curcumin and FDA-approved GLP-1 receptor agonists is too large to bridge with any supplement intervention:

A 100-kg adult on Wegovy can expect roughly 15 kg of weight loss over a year, and on Zepbound roughly 21 kg. The same adult taking 1 g/day of phytosomal curcumin can expect single-digit kilograms of weight loss over similar time, only if they have metabolic syndrome or NAFLD as the underlying phenotype. There is no published peer-reviewed RCT in which curcumin or turmeric has been compared head-to-head with any FDA-approved AOM. Anyone medically qualifying for AOM therapy should not substitute turmeric for the prescription.

For the patient-side “how much will I lose on Wegovy or Zepbound” question, see our semaglutide overview and tirzepatide overview.

7. Dosing — what the trials actually used

Reasonable RCT-aligned dosing for a patient who has decided to try curcumin as a modest adjunct:

Upper limit consideration. Doses above 1.5 g/day of standardized curcumin extract are associated with GI side effects (nausea, diarrhea, abdominal cramping) in a meaningful fraction of users. Doses above 1 g/day of high-bioavailability phytosomal curcumin (Meriva-type) are the formulation pattern most over-represented in the published hepatotoxicity case reports (Lombardi 2021, see Section 8). Higher does NOT equal better. The Panahi 2017 dose of 1 g/day phytosomal curcumin is a reasonable ceiling.

8. Safety — GI, liver, iron, and drug interactions

Culinary turmeric in food is very safe; the WHO/FAO Joint Expert Committee on Food Additives sets the acceptable daily intake of curcumin from food at up to 3 mg/kg body weight per day. The safety questions arise at supplemental, bioavailability-enhanced, gram-scale doses.

8.1 Hepatotoxicity — the most important safety signal

The Lombardi, Crescioli, Maggini, Ippoliti, Menniti-Ippolito, Gallo, Brilli, Lanzi, Mannaioni, Firenzuoli, and Vannacci 2021 analysis of the Italian Phytovigilance database^[7] is the most rigorous safety document we have. The abstract states, verbatim:

“Several cases of acute non-infectious cholestatic hepatitis recently appeared in Italy following consumption of Curcuma longa-containing dietary supplements. ... Seven cases of acute hepatitis occurring in Tuscany up to September 2019 are described. In all cases, hepatotoxicity was associated with Curcuma longa formulations with high bioavailability and high dosage of curcumin/curcuminoids. ... In the 23 cases identified through the systematic review, the majority of patients were concomitantly exposed to at least one other medication ... the evaluation of Italian cases of Curcuma longa-induced acute hepatitis and the systematic review of literature confirmed the association between Curcuma longa and liver injury.”^[7]

The hepatotoxicity pattern is consistent across reports: cholestatic or mixed hepatitis, jaundice, dark urine, fatigue, elevated alkaline phosphatase, with onset typically 1 to 4 months after starting a high-bioavailability formulation at gram-scale doses. The mechanism is not fully established and may include idiosyncratic immune-mediated injury rather than direct dose-dependent toxicity. The NIH LiverTox monograph for turmeric/curcumin classifies the risk as moderate and explicitly names piperine-enhanced and phytosomal high-dose products as the problematic forms.

Practical guidance:

• Do not start daily gram-scale curcumin if you have a known chronic liver condition (NAFLD, hepatitis B/C, autoimmune hepatitis, cirrhosis, prior drug-induced liver injury) without a prescriber's sign-off and a baseline AST/ALT/ALP.
• Stop curcumin immediately and see a clinician if you develop jaundice (yellow skin or eyes), dark cola-colored urine, pale clay-colored stools, severe fatigue, persistent right-upper-quadrant abdominal pain, or unexplained nausea and itching.
• On any GLP-1 (Wegovy, Zepbound, Ozempic, Mounjaro, compounded), nausea and fatigue are common during titration and can mask early hepatotoxicity symptoms. If new GI or fatigue symptoms appear after starting curcumin, suspect the curcumin first.

8.2 GI side effects

At supplemental doses of 1 to 2 g/day of standardized extract, GI side effects (nausea, mild diarrhea, abdominal cramping, acid reflux) occur in a meaningful minority of users. Taking the capsule with a fat-containing meal reduces GI tolerability problems and also slightly improves absorption (curcumin is lipid-soluble). For GLP-1 users already managing nausea during dose escalation, layering daily gram-scale curcumin is likely to compound symptoms. Consider deferring curcumin until you are stable on a maintenance GLP-1 dose. For the GLP-1 nausea framework, see our GLP-1 side-effect Q&A hub (Spanish) and the English Q&A hub linked from the supplement evidence-grade page.

8.3 Iron absorption and iron-deficiency anemia

Curcumin is a biologically active iron chelator. Jiao, Wilkinson, Di, Wang, Hatcher, Kock, D'Agostino, Knovich, Torti, and Torti 2009^[8] showed that mice on graded dietary iron and curcumin developed reductions in spleen and liver iron and shifts toward iron deficiency under low-iron conditions, with curcumin acting as a direct chelator of Fe3+. Verbatim from the abstract: “Curcumin ... exhibits properties of an iron chelator ... mice were placed on diets containing graded concentrations of both iron and curcumin for 26 weeks ... Mice receiving the lowest level of dietary iron exhibited borderline iron deficiency.”^[8]

Practical guidance: patients with known iron-deficiency anemia, menstruating women with marginal ferritin, pregnant women, post-bariatric patients (already at chronic risk of iron, B12, and other micronutrient deficits), and patients with chronic-disease anemia should NOT take gram-scale daily curcumin without ferritin monitoring and a prescriber's sign-off. Culinary turmeric in food does not produce clinically meaningful iron chelation.

8.4 Drug interactions — anticoagulants, antiplatelets, antidiabetics, thyroid

The drug-interaction picture is mixed. The one published clinical interaction RCT^[6] measured bleeding time and INR before and after 10 days of Meriva 1 g/day in patients on aspirin, ticlopidine, clopidogrel, warfarin, or dabigatran, and separately assessed thyroid function in levothyroxine-treated hypothyroid patients and HbA1c in metformin-treated diabetics. The trial concluded, verbatim: “Results from this non-interaction clinical study suggest that Meriva does not interfere with the antiplatelet activity of the most common antiplatelet drugs. ... In the analyzed patients assuming LT4 or metformin, no interactions between the therapy and Meriva were observed.”^[6]

Counterweight: this is a single, short, industry-affiliated trial with small subgroups. Case reports of warfarin INR elevations and bleeding events on curcumin do exist in the broader post-marketing literature, and in vitro evidence supports antiplatelet activity at the platelet aggregation level. The pragmatic guidance below assumes a non-zero interaction risk:

8.5 Pregnancy and breastfeeding

Culinary turmeric in food is generally considered safe in pregnancy. Supplemental curcumin in gram doses has not been adequately studied in pregnancy and should be avoided. Curcumin has uterotonic activity in some animal models, and traditional Ayurvedic use cautioned against high-dose turmeric in pregnancy. Patients trying to conceive, pregnant, or breastfeeding should limit turmeric to culinary use.

9. The TikTok and “golden milk” angle

“Golden milk” turmeric latte recipes circulate on TikTok and wellness Instagram with weight-loss claims that invariably overshoot the evidence base. Typical recipes contain 1/2 to 1 teaspoon of turmeric powder, a pinch of black pepper, ginger, milk or non-dairy milk, and honey or maple syrup. The curcumin dose delivered is on the order of 50 to 100 mg per cup — well below RCT-active levels. The black pepper does meaningfully improve bioavailability of the small dose that is there, but a single golden-milk cup still provides 1/5 to 1/10 the curcumin dose used in the Panahi 2017 NAFLD trial.

Net assessment: golden milk is a pleasant warm beverage with a modest anti-inflammatory dose of curcumin. It is not a weight-loss drink, and the added milk-and-sweetener calories often offset any metabolic benefit. If you enjoy it as a zero-sweetener evening beverage, fine; if you are drinking it with the expectation of meaningful weight loss, the evidence does not support that expectation. Substituting it for a 200 kcal sweetened latte is the most defensible mechanism by which it helps weight, and that mechanism is calorie substitution, not curcumin pharmacology.

10. How turmeric compares to other modest-effect supplements

Within the broader supplement-evidence-grade framework, turmeric sits in the same evidence-grade neighborhood as several other modest-effect, single-digit-percent supplements:

The pattern across the supplement column is consistent: every well-studied supplement produces a small effect (typically 1 to 3 kg over 2 to 6 months), every prescription anti-obesity medication produces a large effect (15 to 21 percent of body weight over 12 to 18 months), and the gap between the two classes is roughly an order of magnitude. Turmeric is not the exception.

11. Should you take turmeric for weight loss?

The honest, evidence-led answer for most readers: no, turmeric is not the right primary tool if weight loss is the goal. Three caveats refine this:

• Reasonable yes, if your phenotype is inflammation-driven obesity. If you have NAFLD, elevated CRP, metabolic syndrome, or elevated ALT/AST, a 1 g/day phytosomal curcumin or 500 to 1,000 mg/day standardized curcumin + piperine for 8 to 12 weeks is a defensible adjunct, particularly if your prescriber is monitoring liver enzymes anyway. Magnitude expectation: single-digit kg over 2 to 3 months.
• Reasonable add-on, if you are already on a GLP-1 and targeting liver outcomes. A patient on Wegovy or Zepbound for obesity who also has NAFLD may see additive (not synergistic) ALT/AST improvement from layered phytosomal curcumin. Defer until you are stable on the GLP-1 maintenance dose to avoid stacked GI side effects during titration.
• Not appropriate as a stand-in for a GLP-1 if you medically qualify. Patients with BMI ≥ 30 or BMI ≥ 27 with weight-related comorbidity who have access to a covered or self-pay AOM should not substitute curcumin. The magnitude gap is too large and the time loss matters.

For the broader supplement-vs-AOM evidence framework, see our supplements weight-loss evidence-grade hub. Curcumin/turmeric sits in the C grade neighborhood within that framework: modest evidence, modest effect, real but narrow population.

12. Disclaimers

Turmeric and curcumin extracts are sold in the US under the Dietary Supplement Health and Education Act (DSHEA) of 1994. The FDA does not review dietary supplements for efficacy before marketing. The standard DSHEA disclaimer applies: these products have not been evaluated by the Food and Drug Administration, are not intended to diagnose, treat, cure, or prevent any disease, and should not be substituted for medical advice or medical intervention.

This article is for informational purposes only. It is not medical advice and does not replace a clinical evaluation by a licensed healthcare provider. Patients with any chronic medical condition, on prescription medication, pregnant, breastfeeding, scheduled for surgery, or with prior liver injury or iron-deficiency anemia should discuss curcumin supplements with their prescriber before starting.

13. Related research

For the full 16-supplement evidence-grade matrix that places turmeric in context with berberine, ashwagandha, green tea, MCT oil, glucomannan, magnesium, garcinia, chromium, CLA, and others, see our supplements weight-loss evidence-grade hub. Turmeric/curcumin is graded C in that framework.

For the cortisol-modulation adaptogen with the closest mechanism analogy (chronic-stress-mediated weight modulation through a different but parallel pathway), see our ashwagandha weight-effects evidence review.

For the AMPK-pathway parallel supplement that is sometimes marketed alongside curcumin as a “natural metformin” / “natural Ozempic” combo, see our berberine vs GLP-1 evidence review.

For the GLP-1 + NAFLD/NASH literature that informs the liver-outcomes case for or against curcumin co-administration, see our does GLP-1 cause liver damage? NAFLD/NASH evidence review.

For the parallel thermogenesis-pathway supplement (EGCG + caffeine via COMT inhibition) with a similarly modest pooled-trial effect size, see our matcha for weight loss evidence review.

For a nutrient-dense leaf supplement with overlapping anti-inflammatory and polyphenol mechanism claims but weaker placebo-controlled human RCT evidence than curcumin, see our moringa for weight loss evidence review.

For the broader fruits-and-foods context that often accompanies “does X help with weight loss” queries, see our fruits for weight loss evidence hub.